The news of RBC Capital reiterating a Sector Perform rating and maintaining a $17 price target for Intercept Pharma (ICPT) is neutral for the stock. The rating suggests that the stock is expected to perform in line with the market, and the price target is unchanged. This information is relevant and important for investors, but it does not indicate a significant change in the stock's outlook.